OLMA News and Press, Olema Pharmaceuticals Inc. From 11/30/21

Successful completion of dose-escalation stage of ongoing Phase 1/2 clinical study; OP-1250 demonstrated highly attractive pharmacokinetics, favorable tolerability, and clear efficacy signals Robust anti-tumor activity, including three partial responses (two confirmed and one ...

Olema Pharmaceurticals (NASDAQ:OLMA) says that there is "falsified information" circulating on social media dealing with a poster presentation on breast cancer candidate OP-1250 at an upcoming medical conference. Trading in the stock was halted at 3:23p ET and did not resume before the market...

SAN FRANCISCO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women&#x...

Interim pharmacokinetic, safety and tolerability, and preliminary efficacy data from Phase 1 dose escalation to be presented Company to host investor webcast at 8:30 a.m. ET on Wednesday, December 8, 2021 SAN FRANCISCO, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Olema P...

Gainers: Longeveron (NASDAQ:LGVN) +36%, SCYNEXIS (NASDAQ:SCYX) +16%, Context Therapeutics (NASDAQ:CNTX) +15%, Akoya Biosciences (NASDAQ:AKYA) +15%, Aspira Women's Health (NASDAQ:AWH) +15%. Losers: Connect Biopharma (NASDAQ:CNTB) -54%, Flora Gr...

Olema Pharmaceuticals (NASDAQ:OLMA): Q3 GAAP EPS of -$0.45 beats by $0.01. Press Release. For further details see: Olema Pharmaceuticals EPS beats by $0.01

Completed dose-escalation stage of Phase 1/2 clinical trial of OP-1250 in patients with metastatic, ER+ / HER2- breast cancer Interim safety, tolerability, pharmacokinetic and initial efficacy data from Phase 1 dose escalation to be presented at 2021 San Antonio Breast...

SAN FRANCISCO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women&#x...

Radius Health (RDUS +15.2%) has recorded the biggest intraday gain since May to reach a three-month high after the company announced that its experimental therapy elacestrant met the primary endpoint in a late-stage trial for certain patients with breast cancer. Out-licensed to Menarini ...

Gainers: Sesen Bio (NASDAQ:SESN) +43%, Radius Health (NASDAQ:RDUS) +29%, Valneva SE (NASDAQ:VALN) +15%, Olema Pharmaceuticals (NASDAQ:OLMA) +15%, First Wave BioPharma (NASDAQ:FWBI) +6%. Losers: ATI Physical Therapy (NYSE:ATIP) -20%, HCW Biologics (...